Skip to main content
. 2017 Mar 15;24(4):472–480. doi: 10.1177/1352458517699874

Figure 2.

Figure 2.

The effect of fingolimod on mtDNA concentration levels (Swedish cohort). To compare baseline and follow-up mtDNA copies in the fingolimod relapsing-remitting multiple sclerosis group (n = 23), a Wilcoxon signed rank test was performed. The follow-up moment lies after 6–12 months.

The horizontal lines correspond to median and interquartile range. *p = 0.012 (z = −2.52, r = −0.37).